Weekly paclitaxel vs three‐weekly paclitaxel
Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐resistant compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
- Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes onlyRR 1.01 [0.55, 2.12]2 studies · 163 participantsVery low